The histone deacetylase inhibitor entinostat/syndax 275 in osteosarcoma

Histone deacetylase inhibitors: molecular mechanisms of action

Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542 · see citing works

Histone Deacetylase Inhibitors as Anticancer Drugs

Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206 · see citing works

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752 · see citing works

Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate

Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D. L., Bernstein, M. L., Conrad, E. U., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717 · see citing works

Histone deacetylase inhibitors: Potential in cancer therapy

Marks, P. A., & Xu, W. ‐. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22185 · Cited by 716 · see citing works

Biology and Therapeutic Advances for Pediatric Osteosarcoma

Marina, N. M., Gebhardt, M. C., Teot, L. A., & Gorlick, R. G. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-422 · Cited by 663 · see citing works

Primary bone osteosarcoma in the pediatric age: State of the art

Longhi, A., Errani, C., PAOLIS, M. D., Mercuri, M., & Bacci, G. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.05.005 · Cited by 630 · see citing works

Prospects: Histone deacetylase inhibitors

Dokmanovic, M., & Marks, P. A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20532 · Cited by 480 · see citing works

Histone deacetylases and cancer

Barneda‐Zahonero, B., & Parra, M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.07.003 · Cited by 449 · see citing works

Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover.

French, L. E., Hahne, M., Viard, I., Radlgruber, G., Zanone, R., Becker, K., Müller, C., & Tschopp, J. (1996) · The Journal of Cell Biology · doi:10.1083/jcb.133.2.335 · Cited by 445 · see citing works

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Bielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422 · see citing works

Regulation of CD95/Fas signaling at the DISC

Lavrik, I. N., & Krammer, P. H. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.155 · Cited by 357 · see citing works

Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights

Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 282 · see citing works

Histone Deacetylase Inhibitors Trigger a G2 Checkpoint in Normal Cells That Is Defective in Tumor Cells

Qiu, L., Burgess, A., Fairlie, D. P., Leonard, H. P., Parsons, P. G., & Gabrielli, B. G. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.6.2069 · Cited by 249 · see citing works

Gemcitabine in the Treatment of Refractory Hodgkin’s Disease: Results of a Multicenter Phase II Study

Santoro, A., Bredenfeld, H., Devizzi, L. F., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2615 · Cited by 230 · see citing works

Apicidin, a Histone Deacetylase Inhibitor, Induces Apoptosis and Fas/Fas Ligand Expression in Human Acute Promyelocytic Leukemia Cells

Kwon, S. H., Ahn, S., Kim, Y. K., Bae, G., Yoon, J., Hong, S., Lee, H. Y., Lee, Y., Lee, H.-W., & Han, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106699200 · Cited by 215 · see citing works

c-FLIP inhibits chemotherapy-induced colorectal cancer cell death

Longley, D. B., Wilson, T. R., McEwan, M. V., Allen, W. L., McDermott, U., Galligan, L., & Johnston, P. G. (2005) · Oncogene · doi:10.1038/sj.onc.1209122 · Cited by 201 · see citing works

Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions

Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000065 · Cited by 197 · see citing works

Programmed Cell Death Ligand 1 Expression in Osteosarcoma

Shen, J. K., Cote, G. M., Choy, E., Yang, P., Harmon, D. C., Schwab, J. H., Nielsen, G. P., Chebib, I. A., Ferrone, S., Wang, X., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0224 · Cited by 195 · see citing works

Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8–mediated apoptosis and down-regulation of c-FLIP protein

Aron, J. L., Parthun, M. R., Marcucci, G., Kitada, S., Mone, A. P., Davis, M. E., Shen, T., Murphy, T. J., Wickham, J., Kanakry, C. G., et al. (2003) · Blood · doi:10.1182/blood-2002-12-3794 · Cited by 171 · see citing works

Genetic syndromes caused by mutations in epigenetic genes

Berdasco, M., & Esteller, M. (2013) · Human Genetics · doi:10.1007/s00439-013-1271-x · Cited by 165 · see citing works

Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma

Marchi, E., Alinari, L., Tani, M., et al. (2005) · Cancer · doi:10.1002/cncr.21449 · Cited by 161 · see citing works

Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma

Navid, F., Willert, J. R., McCarville, M. B., Furman, W. L., Watkins, A., Roberts, W., & Daw, N. C. (2008) · Cancer · doi:10.1002/cncr.23586 · Cited by 153 · see citing works

A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies

Jia, S.-F., Worth, L. L., & Kleinerman, E. S. (1999) · Clinical & Experimental Metastasis · doi:10.1023/a:1006623001465 · Cited by 146 · see citing works

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells

Lucas, D. M., Davis, M. E., Parthun, M. R., Mone, A. P., Kitada, S., Cunningham, K. D., Flax, E. L., Wickham, J., Reed, J. C., Byrd, J. C., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403388 · Cited by 135 · see citing works

HDAC inhibitors still need a home run, despite recent approval

Guha, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4583 · Cited by 120 · see citing works

Selective Expression of FLIP in Malignant Melanocytic Skin Lesions

Bullani, R. R., Huard, B., Viard‐Leveugle, I., et al. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01418.x · Cited by 111 · see citing works

Overexpression of the thymosin β-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma

Wang, W.-S., Chen, P., Hsiao, H.-L., Wang, H.-S., Liang, W.-Y., & Su, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1207888 · Cited by 106 · see citing works

Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP

Watanabe, K., Okamoto, K., & Yonehara, S. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401507 · Cited by 102 · see citing works

9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice.

Koshkina, N. V., Kleinerman, E. S., Waidrep, C., Jia, S.-F., Worth, L. L., Gilbert, B. E., & Knight, V. (2000) · PubMed · Cited by 101 · see citing works

Phase II trial of gemcitabine in advanced sarcomas

Okuno, S. H., Edmonson, J. H., Mahoney, M. R., et al. (2002) · Cancer · doi:10.1002/cncr.10602 · Cited by 99 · see citing works

Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.

Palmerini, E., Jones, R. L., Marchesi, E., Paioli, A., Cesari, M., Longhi, A., Meazza, C., Coccoli, L., Fagioli, F., Asaftei, S., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2312-3 · Cited by 98 · see citing works

Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma

Wang, W.-S., Chen, P., Wang, H.-S., Liang, W.-Y., & Su, Y. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi351 · Cited by 95 · see citing works

Increased Fas Expression Reduces the Metastatic Potential of Human Osteosarcoma Cells

Lafleur, E. A., Koshkina, N. V., Stewart, J. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0353 · Cited by 92 · see citing works

Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases

Koshkina, N. V., & Kleinerman, E. S. (2005) · International Journal of Cancer · doi:10.1002/ijc.21011 · Cited by 85 · see citing works

Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus

Ikeda, G., Isaji, S., Das, B. C., Watanabe, M., & Kawarada, Y. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991015)86:8 · Cited by 82 · see citing works

Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma

Anderson, P. M., Wiseman, G. A., Erlandson, L., Rodriguez, V., Trotz, B. A., Dubansky, S. A., & Albritton, K. H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0628 · Cited by 82 · see citing works

Fas expression inversely correlates with metastatic potential in osteosarcoma cells

Worth, L. L., Lafleur, E. A., Jia, S.-F., & Kleinerman, E. S. (2002) · Oncology Reports · doi:10.3892/or.9.4.823 · Cited by 77 · see citing works

Phase II trial of gemcitabine in patients with advanced sarcomas (E1797)

Okuno, S. H., RYAN, L. M., Edmonson, J. H., et al. (2003) · Cancer · doi:10.1002/cncr.11290 · Cited by 76 · see citing works

Gemcitabine in Combination With Doxorubicin in Advanced Breast Cancer: Final Results of a Phase II Pharmacokinetic Trial

Pérez-Manga, G., Lluch, A. M., Alba, E., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2545 · Cited by 72 · see citing works

c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations

Korkolopoulou, P. A., Goudopoulou, A., Voutsinas, G. E., et al. (2004) · Urology · doi:10.1016/j.urology.2004.01.007 · Cited by 71 · see citing works

Corruption of the Fas Pathway Delays the Pulmonary Clearance of Murine Osteosarcoma Cells, Enhances Their Metastatic Potential, and Reduces the Effect of Aerosol Gemcitabine

Gordon, N. B., Koshkina, N. V., Jia, S.-F., Khanna, C., Mendoza, A., Worth, L. L., & Kleinerman, E. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0313 · Cited by 68 · see citing works

Untitled work

(2003) · PubMed · Cited by 67 · see citing works

Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs

Marconato, L., Lorenzo, R. M., Abramo, F., et al. (2008) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2007.00143.x · Cited by 65 · see citing works

The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin

Wittenburg, L. A., Bisson, L., Rose, B. J., Korch, C. T., & Thamm, D. H. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1287-z · Cited by 65 · see citing works

Fas-Negative Osteosarcoma Tumor Cells Are Selected during Metastasis to the Lungs: The Role of the Fas Pathway in the Metastatic Process of Osteosarcoma

Koshkina, N. V., Khanna, C., Mendoza, A., Guan, H., DeLauter, L., & Kleinerman, E. S. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0007 · Cited by 64 · see citing works

True

Volm, M., & Koomägi, R. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1210 · Cited by 63 · see citing works

Combinatorial Treatment of DNA and Chromatin-Modifying Drugs Cause Cell Death in Human and Canine Osteosarcoma Cell Lines

Thayanithy, V., Park, C., Sarver, A. L., Kartha, R. V., Korpela, D. M., Graef, A. J., Steer, C. J., Modiano, J. F., & Subramanian, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043720 · Cited by 63 · see citing works

FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells

Imai, T., Adachi, S., Nishijo, K., Ohgushi, M., Okada, M., Yasumi, T., Watanabe, K.-I., Nishikomori, R., Nakayama, T., Yonehara, S., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1207184 · Cited by 63 · see citing works

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)

Martín‐Broto, J., Redondo, A., Valverde, C. M., Vaz, M. A., Mora, J., del Muro, X. G., Gutierrez, A. M., Tous, C., Carnero, A., Marcilla, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx536 · Cited by 59 · see citing works

Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas

Rapkin, L. B., Qayed, M. D., Brill, P., Martin, M., Clark, D., George, B. A., Olson, T. A., Wasilewski‐Masker, K. J., Alazraki, A. L., & Katzenstein, H. M. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24101 · Cited by 56 · see citing works

Depsipeptide (FR901228) Inhibits Proliferation and Induces Apoptosis in Primary and Metastatic Human Uveal Melanoma Cell Lines

Klisovic, D. D., Katz, S. E., Effron, D., et al. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-1052 · Cited by 55 · see citing works

Leucine‐rich repeat neuronal protein‐1 suppresses apoptosis of gastric cancer cells through regulation of Fas/FasL

Liu, B., Zhang, Y., Fan, Y., et al. (2019) · Cancer Science · doi:10.1111/cas.14042 · Cited by 54 · see citing works

Separate and Combined Effects of DNMT and HDAC Inhibitors in Treating Human Multi-Drug Resistant Osteosarcoma HosDXR150 Cell Line

Capobianco, E., Mora, A., Sala, D. L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095596 · Cited by 49 · see citing works

Aerosol Gemcitabine: Preclinical Safety and In Vivo Antitumor Activity in Osteosarcoma-Bearing Dogs

Rodriguez, C. O., Crabbs, T. A., Wilson, D. W., et al. (2009) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2009.0773 · Cited by 48 · see citing works

Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis

Zhu, Z., Jin, Z., Zhang, M., Tang, Y., Yang, G., Yuan, X., Yao, J., & Sun, D. (2017) · Oncotarget · doi:10.18632/oncotarget.19168 · Cited by 45 · see citing works

A new therapeutic combination for osteosarcoma: Gemcitabine and Clofazimine co-loaded liposomal formulation

Caliskan, Y., Dalgıç, A. D., Gerekçi, S., Taşkıran, A. E. G., Tezcaner, A., Özen, C., & Keskin, D. S. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.12.041 · Cited by 45 · see citing works

The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases

Rao‐Bindal, K., Koshkina, N. V., Stewart, J., & Kleinerman, E. S. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313040005 · Cited by 43 · see citing works

Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin

Wagner‐Bohn, A., Paulussen, M., Pinheiro, J. P. V., et al. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000217426.82702.74 · Cited by 42 · see citing works

Aerosol interleukin‐2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis

Guma, S. R., Lee, D. A., Yu, L., Gordon, N. B., & Kleinerman, E. S. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25019 · Cited by 40 · see citing works

Aerosol Therapy for the Treatment of Osteosarcoma Lung Metastases: Targeting the Fas/FasL Pathway and Rationale for the Use of Gemcitabine

Gordon, N. B., & Kleinerman, E. S. (2010) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2009.0812 · Cited by 40 · see citing works

Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation

Deng, Z., Liu, X., Jin, J., Xu, H., Gao, Q., Wang, Y., & Zhao, J. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.16569 · Cited by 38 · see citing works

Adjuvant Carboplatin and Gemcitabine Combination Chemotherapy Postamputation in Canine Appendicular Osteosarcoma

McMahon, M. B., Mathie, T., Stingle, N., et al. (2011) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2011.0697.x · Cited by 37 · see citing works

Role of MRIT/cFLIP in Protection Against Chemotherapy-Induced Apoptosis

Matta, H., Eby, M. T., Gazdar, A. F., et al. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.315 · Cited by 33 · see citing works

Expression of Cellular FLICE Inhibitory Protein, Caspase-8, and Protease Inhibitor-9 in Ewing Sarcoma and Implications for Susceptibility to Cytotoxic Pathways

de Hooge, A. S. K., Berghuis, D., Santos, S. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1457 · Cited by 32 · see citing works

PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells

Valle, N. R.-D., Gao, S., Miller, C. P., Fulbright, J. M., Gonzales, C., Sirisawad, M., Steggerda, S. M., Wheler, J. J., Balasubramanian, S., & Chandra, J. (2010) · International Journal of Cell Biology · doi:10.1155/2010/207420 · Cited by 31 · see citing works

Effect of the histone deacetylase inhibitor SNDX‐275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases

Koshkina, N. V., Rao‐Bindal, K., & Kleinerman, E. S. (2011) · Cancer · doi:10.1002/cncr.25884 · Cited by 31 · see citing works

Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines

Ando, T., Ichikawa, J., Okamoto, A., et al. (2005) · Journal of Orthopaedic Research® · doi:10.1016/j.orthres.2005.01.010 · Cited by 30 · see citing works

Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications

Chaiyawat, P., Pruksakorn, D., Phanphaisarn, A., Teeyakasem, P., Klangjorhor, J., & Settakorn, J. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.125 · Cited by 30 · see citing works

Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death

Yamanegi, K. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1438 · Cited by 27 · see citing works

Downregulation of IFN‐γR in association with loss of Fas function is linked to tumor progression

Yang, D., Stewart, T. J., Smith, K. K., Georgi, D. E., Abrams, S. I., & Liu, K. (2007) · International Journal of Cancer · doi:10.1002/ijc.23090 · Cited by 26 · see citing works

Alterations in Fas Expression Are Characteristic of, But Not Solely Responsible for, Enhanced Metastatic Competence

Liu, K., & Abrams, S. I. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.5973 · Cited by 23 · see citing works

Expression of c‐FLIP in pulmonary metastases in osteosarcoma patients and human xenografts

Rao‐Bindal, K., Rao, C. K., Yu, L., & Kleinerman, E. S. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24412 · Cited by 23 · see citing works

Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine‐Docetaxel Chemotherapy

Lee, J. A., Jeon, D., Cho, W. H., Song, W. S., Yoon, H. S., Park, H. J., Park, B. K., Choi, H. S., Ahn, H. S., Lee, J. W., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26058 · Cited by 21 · see citing works

Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines

Pettke, A., Hotfilder, M., Clemens, D., Klco‐Brosius, S., Schaefer, C., Potratz, J. C., & Dirksen, U. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000418 · Cited by 21 · see citing works

Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro

McMahon, M. B., Bear, M. D., Kulp, S. K., et al. (2010) · American Journal of Veterinary Research · doi:10.2460/ajvr.71.7.799 · Cited by 20 · see citing works

Licoricidin enhances gemcitabine-induced cytotoxicity in osteosarcoma cells by suppressing the Akt and NF-κB signal pathways

Wang, Y., Wang, S., Liu, J., Lu, Y., & Li, D. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.05.007 · Cited by 20 · see citing works

Single Agent Gemcitabine Chemotherapy in Dogs with Spontaneously Occurring Lymphoma

Turner, A. I., Hahn, K. A., Rusk, A. W., et al. (2006) · Journal of Veterinary Internal Medicine · doi:10.1892/0891-6640(2006)20[1384:sagcid]2.0.co;2 · Cited by 19 · see citing works

Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.

Rizzieri, D. A., Ibom, V. K., Moore, J. O., et al. (2003) · PubMed · Cited by 19 · see citing works

Single Agent Gemcitabine Chemotherapy in Dogs with Spontaneously Occurring Lymphoma

Turner, A. I., Hahn, K. A., Rusk, A. W., et al. (2006) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2006.tb00755.x · Cited by 18 · see citing works

In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells

Gravett, A. M., Dalgleish, A. G., & Copier, J. P. (2019) · Scientific Reports · doi:10.1038/s41598-018-38190-2 · Cited by 17 · see citing works

Gemcitabine sensitizes pancreatic cancer cells to the CTLs antitumor response induced by BCG-stimulated dendritic cells via a Fas-dependent pathway

Pei, Q., Pan, J., Ding, X., Wang, J., Zou, X., & Lv, Y. (2015) · Pancreatology · doi:10.1016/j.pan.2015.04.001 · Cited by 12 · see citing works

Synergistic antitumor effect of suberoylanilide hydroxamic acid and cisplatin in osteosarcoma cells

Hou, M., Huang, Z., Chen, S., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9224 · Cited by 12 · see citing works

Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study

Hara, H., Kawamoto, T., Fukase, N., Kawakami, Y., Takemori, T., Fujiwara, S., Kitayama, K., Nishida, K., Kuroda, R., & Akisue, T. (2019) · BMC Cancer · doi:10.1186/s12885-019-5923-7 · Cited by 11 · see citing works

Gemcitabine in Bone Sarcoma Resistant to Doxorubicin‐BasedChemotherapy

Merimsky, O., Meller, I., Kollender, Y., Issakov, J., Flusser, G., & Inbar, M. (2000) · Sarcoma · doi:10.1155/s1357714x00000025 · Cited by 8 · see citing works

Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.

Zak, D., Styler, M. J., Rosenbluth, J. Z., et al. (2005) · PubMed · Cited by 7 · see citing works

The role of protein acetylation in carcinogenesis and targeted drug discovery

Yang, J., Song, C., & Zhan, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.972312 · Cited by 42 · see citing works

Entinostat improves motor function and neuronal damage Via downregulating NLRP3 inflammasome activation after spinal cord injury

Dai, C., Liu, B., Peng, B., Qu, B., Lin, J., Peng, B., & Li, D.-M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.774539 · Cited by 19 · see citing works

Epigenetic modifications of inflammation in spinal cord injury

Lu, Z.-J., Pan, Q.-L., & Lin, F.-X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117306 · Cited by 14 · see citing works

Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook

Lv, L.-Z., Wang, Z.-D., Ren, J.-J., Li, L.-H., Liu, X.-B., Li, J.-L., Zhu, H., Jiang, B., Han, Y.-P., Zhou, X.-M., et al. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2025.1722453 · Cited by 7 · see citing works

Inhibition of Class IIb Histone Deacetylase Significantly Improves Cloning Efficiency in Mice1

Ono, T., Li, C., Mizutani, E., Terashita, Y., Yamagata, K., & Wakayama, T. (2010) · Biology of Reproduction · doi:10.1095/biolreprod.110.085282 · Cited by 112 · see citing works

Supplementary Figures 1-2 from Histone Deacetylase Inhibitor–Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53

Kim, I. A., Shin, J. H., Kim, I. H., et al. (2023) · doi:10.1158/1078-0432.22441545.v1

Supplementary Figures 1-8 from Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737

Wiegmans, A. P., Alsop, A. E., Bots, M. L., et al. (2023) · doi:10.1158/0008-5472.22389305.v1

Recent progress in the development of assays suited for histone deacetylase inhibitor screening

Wegener, D., Hildmann, C., & Schwienhorst, A. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.008 · Cited by 41 · see citing works

Supplementary Figures 1-2 from Histone Deacetylase Inhibitor–Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53

Kim, I. A., Shin, J. H., Kim, I. H., et al. (2023) · doi:10.1158/1078-0432.22441545